23andMe In Collaboration With 20 Lung Cancer Advocacy Organizations, Announced A New Study To Help Advance Research In Lung Cancer

7/25/24 7:36:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ME alert in real time by email

The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies have provided hope and years of survival to many lung cancer patients, lung cancer remains the number one cause of cancer deaths in both men and women in the United States. Yet, much remains unknown about the disease and its causes.

Get the next $ME alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ME

Date	Price Target	Rating	Analyst
11/29/2022	$7.00	Buy	Berenberg
9/22/2022	$6.00	Outperform	Cowen
2/11/2022	$14.00 → $11.00	Outperform	Credit Suisse
12/20/2021	$13.00 → $9.00	Neutral	Citigroup
11/15/2021	$12.00 → $13.00	Buy → Neutral	Citigroup
11/11/2021	$13.00 → $14.00	Outperform	Credit Suisse
8/17/2021	$13.00	Outperform	Credit Suisse
7/12/2021	$14.00	Buy	Citigroup

More analyst ratings

$ME
Market Insights

Live Market Insights

23andMe In Collaboration With 20 Lung Cancer Advocacy Organizations, Announced A New Study To Help Advance Research In Lung Cancer
The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies have provided hope and years of survival to many lung cancer patients, lung cancer remains the number one cause of cancer deaths in both men and women in the United States. Yet, much remains unknown about the disease and its causes.
7/25/24 7:36:06 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
23andMe And Nightingale Health Announced A Strategic Collaboration To Pilot Nightingale Health's Blood Metabolomics Panel With A Cohort Of 23andMe Members
As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale's Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe's established personal genetics products.
6/28/24 7:33:12 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
Looking Into 23andMe Holding's Recent Short Interest
23andMe Holding's (NYSE:ME) short percent of float has fallen 6.06% since its last report. The company recently reported that it has 36.69 million shares sold short, which is 11.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.04 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere
6/12/24 3:15:21 PM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care

23andMe Appoints Three New Independent Directors to Board
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio
10/29/24 7:30:00 AM ET
$ANSS
$CDLX
$LSCC
$ME
Computer Software: Prepackaged Software
Technology
Computer Software: Programming Data Processing
Semiconductors
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
12/12/23 5:31:00 PM ET
$EXAS
$ILMN
$LAB
$ME
Medical Specialities
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac
5/8/23 7:00:00 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p
11/12/24 7:30:00 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23
11/7/24 5:54:12 PM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional
11/7/24 7:30:00 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care

$ME
Press Releases

Fastest customizable press release news feed in the world

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine. The 23andMe genetic and phenotypic healt
11/20/24 7:30:00 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p
11/12/24 7:30:00 AM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing further development of all its therapeutics programs, while evaluating strategic alternatives for its clinical and preclinical assets. The Company is reducing its overall headcou
11/11/24 5:30:00 PM ET
$ME
Biotechnology: Pharmaceutical Preparations
Health Care

23andMe In Collaboration With 20 Lung Cancer Advocacy Organizations, Announced A New Study To Help Advance Research In Lung Cancer

Chat with this insight

Recent Analyst Ratings for $ME

$ME SEC Filings

SEC Form 144 filed by 23andMe Holding Co.

SEC Form 10-Q filed by 23andMe Holding Co.

23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

$ME Market Insights

Live Market Insights